Ovarian cancer: avoiding compromising quality of life during intense chemotherapy sessions

References

• NCI. SEER stat fact sheets: ovary cancer. Surveillance, Epidemiology, and End Results Program, 1975–2012 [Internet]. [cited 2015 Oct 22]. Available from: seer.cancer.gov website
   Google Scholar
• Chase DM, Monk BJ, Wenzel LB, et al. Supportive care for women with gynecologic cancers. Expert Rev Anticancer Ther. 2008 Feb; 8(2): 227–241.
   Google Scholar
• Donovan KA, Donovan HS, Cella D, et al. Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials. J Natl Cancer Inst. 2014;106(7):dju128.
   PubMedGoogle Scholar
• King MT, Stockler MR, Butow P, et al. Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer. Int J Gynecological Cancer. 2014;24(5):865–873. doi:10.1097/IGC.0000000000000167.
   PubMed Web of Science ®Google Scholar
• Davis L, Carpenter J. A systematic review of nonpharmacologic interventions for treatment-related symptoms in women with ovarian cancer. Clin J Oncol Nurs. 2015;19(5):535–542. doi:10.1188/15.CJON.19-05AP.
   PubMed Web of Science ®Google Scholar
• Wright JD, Chen L, Tergas AI, et al. Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet Gynecol. 2015;125(6):1345–1352. doi:10.1097/AOG.0000000000000854.
   PubMed Web of Science ®Google Scholar
• Le T, Leis A, Pahwa P, et al. Quality-of-life issues in patients with ovarian cancer and their caregivers: a review. Obstet Gynecol Surv. 2003;58(11):749–758. doi:10.1097/01.OGX.0000093269.99295.8E.
   PubMed Web of Science ®Google Scholar
• Goff BA, Mandel LS, Melancon CH, et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291(22):2705–2712. doi:10.1001/jama.291.22.2705.
   PubMed Web of Science ®Google Scholar
• Gil KM, Gibbons HE, Jenison EL, et al. Baseline characteristics influencing quality of life in women undergoing gynecologic oncology surgery. Health Qual Life Outcomes. 2007;5:25. doi:10.1186/1477-7525-5-25.
   PubMed Web of Science ®Google Scholar
• Von Gruenigen VE, Huang HQ, Gil KM, et al. The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol. 2012;124(3):379–382. doi:10.1016/j.ygyno.2011.11.032.
   PubMed Web of Science ®Google Scholar
• DiSaia PJ, Creasman WT. Clinical gynecologic oncology [Internet]. Elsevier Health Sciences; 2012. Available from: https://books.google.com/books?hl=en&lr=&id=xJxh22oki6UC&oi=fnd&pg=PP2&dq=clinical+gynecologic+oncology+disaia&ots=A5hdbWxN-a&sig=-_VLPNC5H3LowOA3mGWKSZUs6qQ#v=onepage&q=clinical%20gynecologic%20oncology%20disaia&f=false
   Google Scholar
• Shinde, S, Wanger T, Novotny P, et al. Disease-free ovarian cancer patients report severe pain and fatigue over time: prospective quality of life assessment in a consecutive series. Eur J Gynaecol Oncol. 2014;36(2):155–160.
   Web of Science ®Google Scholar
• Network, N.C.C. Adult cancer pain. NCCN Clin Pract Guidel Oncol. 2016;1(2016):88.
   Google Scholar
• Price M, Bell ML, Sommeijer DW, et al. Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: a prospective population-based study over the last year of life. Gynecol Oncol. 2013;130(1):162–168. doi:10.1016/j.ygyno.2013.03.031.
   PubMed Web of Science ®Google Scholar
• Silver J, Mayer RS. Barriers to pain management in the rehabilitation of the surgical oncology patient. J Surg Oncol. 2007;95(5):427–435. doi:10.1002/jso.20780.
   PubMed Web of Science ®Google Scholar
• Vaz AF, Pinto-Neto AM, Conde DM, et al. Quality of life of women with gynecologic cancer: associated factors. Arch Gynecol Obstet. 2007;276(6):583–589. doi:10.1007/s00404-007-0397-2.
   PubMedGoogle Scholar
• Minig L, Vélez JI, Trimble EL, et al. Changes in short-term health-related quality of life in women undergoing gynecologic oncologic laparotomy: an associated factor analysis. Support Care Cancer. 2013;21(3):715–726. doi:10.1007/s00520-012-1571-z.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cancer: WHO’s cancer pain ladder for adults [Internet]. [cited 2015 Oct 30]. Available from: http://www.who.int/cancer/palliative/painladder/en/
   Google Scholar
• Meyer LA, Nick AM, Shi Q, et al. Perioperative trajectory of patient reported symptoms: a pilot study in gynecologic oncology patients. Gynecol Oncol. 2015;136(3):440–445. doi:10.1016/j.ygyno.2015.01.547.
   PubMed Web of Science ®Google Scholar
• Oh TK, Lim MC, Lee Y, et al. Improved postoperative pain control for cytoreductive surgery in women with ovarian cancer using patient-controlled epidural analgesia. Int J Gynecological Cancer. 2016;26(3):588–593. doi:10.1097/IGC.0000000000000644.
   PubMed Web of Science ®Google Scholar
• Ferguson SE, Malhotra T, Seshan VE, et al. A prospective randomized trial comparing patient-controlled epidural analgesia to patient-controlled intravenous analgesia on postoperative pain control and recovery after major open gynecologic cancer surgery. Gynecol Oncol. 2009;114(1):111–116. doi:10.1016/j.ygyno.2009.03.014.
   PubMed Web of Science ®Google Scholar
• Donovan HS, Ward SE, Sereika SM, et al. Web-based symptom management for women with recurrent ovarian cancer: a pilot randomized controlled trial of the WRITE symptoms intervention. J Pain Symptom Manag. 2014;47(2):218–230. doi:10.1016/j.jpainsymman.2013.04.005.
   PubMed Web of Science ®Google Scholar
• Muscaritoli M, Anker SD, Argilés J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr. 2010;29(2):154–159. doi:10.1016/j.clnu.2009.12.004.
   PubMed Web of Science ®Google Scholar
• Caro MMM, Laviano A, Pichard C. Impact of nutrition on quality of life during cancer. Curr Opin Clin Nutr Metab Care. 2007;10(4):480–487. doi:10.1097/MCO.0b013e3281e2c983.
   PubMed Web of Science ®Google Scholar
• Balogun N, Forbes A, Widschwendter M, et al. Noninvasive nutritional management of ovarian cancer patients: beyond intestinal obstruction. Int J Gynecological Cancer. 2012;22(6):1089–1095. doi:10.1097/IGC.0b013e318256e4d3.
   PubMed Web of Science ®Google Scholar
• Santoso JT, Canada T, Latson B, et al. Prognostic nutritional index in relation to hospital stay in women with gynecologic cancer. Obstet Gynecol. 2000;95(6, Part 1):844–846.
   PubMed Web of Science ®Google Scholar
• Steinbach S, Hummel T, Böhner C, et al. Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol. 2009;27(11):1899–1905. doi:10.1200/JCO.2008.19.2690.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network [Internet]. NCCN guidelines version 2.2013 palliative care, no. 2; 2013. [cited 2015 Nov 11]. Available from: http://oralcancerfoundation.org/treatment/pdf/palliative.pdf.
   Google Scholar
• Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142(4):531–543. doi:10.1016/j.cell.2010.07.011.
   PubMed Web of Science ®Google Scholar
• Hébuterne X, Lemarié E, Michallet M, et al. Prevalence of malnutrition and current use of nutrition support in patients with cancer. JPEN. 2014;38(2):196–204. doi:10.1177/0148607113502674.
   PubMed Web of Science ®Google Scholar
• Brown D, Roberts JA, Elkins TE, et al. Hard choices: the gynecologic cancer patient’s end-of-life preferences. Gynecol Oncol. 1994;55(3):355–362. doi:10.1006/gyno.1994.1306.
   PubMed Web of Science ®Google Scholar
• Mardas M, Jamka M, Mądry R, et al. Dietary habits changes and quality of life in patients undergoing chemotherapy for epithelial ovarian cancer. Support Care Cancer. 2014;23(4):1015–1023. doi:10.1007/s00520-014-2462-2.
   PubMed Web of Science ®Google Scholar
• Mateen F, Jatoi A. Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients. Clin Nutr. 2006;25(5):711–715. doi:10.1016/j.clnu.2006.05.009.
   PubMed Web of Science ®Google Scholar
• Berstein E, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome [Internet]. Cachrane Database Syst Rev. 2005;2. [cited 2015 Nov 11]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15846706
   Google Scholar
• Kropsky B, Shi Y, Cherniack EP. Incidence of deep-venous thrombosis in nursing home residents using megestrol acetate. J Am Med Dir Assoc. 2003;4(5):255–256. doi:10.1097/01.JAM.0000083384.84558.75.
   PubMedGoogle Scholar
• Macciò A, Madeddu C, Gramignano G, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol. 2012;124(3):417–425. doi:10.1016/j.ygyno.2011.12.435.
   PubMed Web of Science ®Google Scholar
• Lumachi F, Mazza F, Ermani M, et al. Talc pleurodesis as surgical palliation of patients with malignant pleural effusion. Analysis of factors affecting survival. Anticancer Res. 2012;32(11):5071–5074.
   PubMed Web of Science ®Google Scholar
• Greimel E, Daghofer F, Petru E. Prospective assessment of quality of life in long term-ovarian cancer survivors. Int J Cancer. 2011;128(12):3005–3011. doi:10.1002/ijc.25642.
   PubMed Web of Science ®Google Scholar
• Parsons SL, Lang MW, Steele RJ. Malignant ascites: a 2-year review from a teaching hospital. EJSO. 1996;22(3):237–239. doi:10.1016/S0748-7983(96)80009-6.
   PubMed Web of Science ®Google Scholar
• Perez R, Godwin A, Hamilton T, et al. Ovarian cancer biology. Semin Oncol. 1991;15(3):186.
   Web of Science ®Google Scholar
• Smolle E, Taucher V, Haybaeck J. Malignant ascites in ovarian cancer and the role of targeted therapeutics. Anticancer Res. 2014;34(4):1553–1561.
   PubMed Web of Science ®Google Scholar
• Eskander RN, Tewari KS. Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Int J Womens Health. 2012;4:395–404. doi:10.2147/IJWH.S29467.
   PubMedGoogle Scholar
• Burges A, Wimberger P, Kümper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM× anti-CD3 antibody: a phase I/II study. Clin Cancer Res. 2007;13(13):3899–3905. doi:10.1158/1078-0432.CCR-06-2769.
   PubMed Web of Science ®Google Scholar
• Moughon DL, He H, Schokrpur S, et al. Macrophage blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant ascites in late-stage epithelial ovarian cancer. Cancer Res. 2015;75(22):4742–4752. doi:10.1158/0008-5472.CAN-14-3373.
   PubMed Web of Science ®Google Scholar
• Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209–2221. doi:10.1002/ijc.25423.
   PubMed Web of Science ®Google Scholar
• Parsons SL, Kutarska E, Koralewski P, et al. Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: results of a phase II/III study. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2007;25(18):5520.
   Google Scholar
• Colombo N, Mangili G, Mammoliti S, et al. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol. 2012;125(1):42–47. doi:10.1016/j.ygyno.2011.11.021.
   PubMed Web of Science ®Google Scholar
• Gotlieb WH, Amant F, Advani S, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012;13(2):154–162. doi:10.1016/S1470-2045(11)70338-2.
   PubMed Web of Science ®Google Scholar
• Tuca A, Guell E, Martinez-Losada E, et al. Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res. 2012;4:159.
   PubMedGoogle Scholar
• Halkia E, Papantziala A, Vassiliadou D, et al. Short bowel syndrome after cytoreductive surgery and HIPEC: nutritional considerations. Off J Balkan Union Oncol. 2014;19(2):549.
   PubMed Web of Science ®Google Scholar
• Caceres A, Zhou Q, Iasonos A, et al. Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series. Gynecol Oncol. 2008;108(3):482–485. doi:10.1016/j.ygyno.2007.11.035.
   PubMed Web of Science ®Google Scholar
• Jutzi L, Russell D, Ho S, et al. The role of palliative colorectal stents in gynaecologic malignancy. Gynecol Oncol. 2014;134(3):566–569. doi:10.1016/j.ygyno.2014.06.020.
   PubMed Web of Science ®Google Scholar
• Di Maio M, Bria E, Banna GL, et al. Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors. Anticancer Drugs. 2013;24(2):99–111. doi:10.1097/CAD.0b013e328359d7ba.
   PubMed Web of Science ®Google Scholar
• Sun CC, Bodurka DC, Donato ML, et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol. 2002;87(1):118–128.
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS. Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. J Support Oncol. 2007;5(2 Suppl 1):5–12.
   PubMedGoogle Scholar
• Schwartzberg L, Szabo S, Gilmore J, et al. Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC). Curr Med Res Opin. 2011;27(4):837–845. doi:10.1185/03007995.2011.556603.
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? Oncology. 2007;21(8):946–953.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Bierman PJ, Bradbury B, et al. Antiemesis clinical practice guidelines in oncology. JNCCN. 2004;2(5):470.
   Google Scholar
• National Comprehensive Cancer Network. Nausea and vomiting. Patient and Caregiver Resources; 2015. Available from: https://www.nccn.org/patients/resources/life_with_cancer/managing_symptoms/preventing_nausea.aspx
   Google Scholar
• Jordan K, Gralla R, Jahn F, et al. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol. 2014;722:197–202. doi:10.1016/j.ejphar.2013.09.073.
   PubMed Web of Science ®Google Scholar
• Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189–4198. doi:10.1200/JCO.2010.34.4614.
   PubMed Web of Science ®Google Scholar
• Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(suppl 5):v232–v243. doi:10.1093/annonc/mdq194.
   PubMed Web of Science ®Google Scholar
• Tipton JM, McDaniel RW, Barbour L, et al. Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2007;11(1):69. doi:10.1188/07.CJON.69-78.
   PubMedGoogle Scholar
• Kris MG, Kris MG, Hesketh PJ, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24(18):2932–2947. doi:10.1200/JCO.2006.06.9591.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482–2494. doi:10.1056/NEJMra0706547.
   PubMed Web of Science ®Google Scholar
• Smith GF, Toonen TR. Primary care of the patient with cancer. Am Fam Physician. 2007;75(8):1207.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN guidelines version 1.2016 cancer-related fatigue, Vol. 2016, no. 1; 2016. Available from: https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf
   Google Scholar
• Clevenger L, Schrepf A, Degeest K, et al. Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis. Cancer. 2013;119(17):3234–3241. doi:10.1002/cncr.28188.
   PubMed Web of Science ®Google Scholar
• Donovan HS, Ward S. Representations of fatigue in women receiving chemotherapy for gynecologic cancers. Oncol Nurs Forum. 2005. doi:10.1188/05.ONF.113-116.
   PubMed Web of Science ®Google Scholar
• Le Saux O, Taylor A, Chia V, et al. Cross-sectional study on comorbidities and adverse events in patients with advanced and recurrent ovarian cancer in France. Clin Epidemiol. 2015;7:431.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN guidelines version 2.2016 cancer- and chemotherapy-induced anemia; 2016. Available from: https://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf
   Google Scholar
• Pignata S, De Placido S, Biamonte R, et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer. 2006;6(1):5. doi:10.1186/1471-2407-6-5.
   PubMed Web of Science ®Google Scholar
• Huang H, Brady MF, Cella D, et al. Validation and reduction of FACT/GOG‐Ntx subscale for platinum/paclitaxel‐induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecological Cancer. 2007;17(2):387–393. doi:10.1111/j.1525-1438.2007.00794.x.
   PubMed Web of Science ®Google Scholar
• Ezendam NP, Pijlman B, Bhugwandass C, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol. 2014;135(3):510–517. doi:10.1016/j.ygyno.2014.09.016.
   PubMed Web of Science ®Google Scholar
• Barrett-Lee P, Bokemeyer C, Gascón P, et al. Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist. 2005;10(9):743–757. doi:10.1634/theoncologist.10-9-743.
   PubMed Web of Science ®Google Scholar
• Wolf S, Barton D, Kottschade L, et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44(11):1507–1515. doi:10.1016/j.ejca.2008.04.018.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Bogliun G, Marzorati L, et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol. 2004;15(9):1439–1442. doi:10.1093/annonc/mdh348.
   PubMed Web of Science ®Google Scholar
• Hosseinimehr SJ. Trends in the development of radioprotective agents. Drug Discov Today. 2007;12(19):794–805. doi:10.1016/j.drudis.2007.07.017.
   PubMed Web of Science ®Google Scholar
• Argyriou A, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology. 2005;64(1):26–31. doi:10.1212/01.WNL.0000148609.35718.7D.
   PubMed Web of Science ®Google Scholar
• Moonsammy SH, Guglietti CL, Santa Mina D, et al. A pilot study of an exercise & cognitive behavioral therapy intervention for epithelial ovarian cancer patients. J Ovarian Res. 2013 Apr 4;6(1):21.
   Google Scholar
• Albers J, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003412.
   Google Scholar
• Hilpert F, Stähle A, Tomé O, et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer. 2005;13(10):797–805. doi:10.1007/s00520-005-0782-y.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Chroni E, Koutras A, et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer. 2006;14(11):1134–1140. doi:10.1007/s00520-006-0072-3.
   PubMed Web of Science ®Google Scholar
• Tucker PE, Bulsara MK, Salfinger SG, et al. Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy. Gynecol Oncol. 2016 Jan;140(1):95–100.
   Google Scholar
• Liavaag AH, Dørum A, Bjøro T, et al. A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach. Gynecol Oncol. 2008;108(2):348–354. doi:10.1016/j.ygyno.2007.10.009.
   PubMed Web of Science ®Google Scholar
• Stead ML, Fallowfield L, Selby P, et al. Psychosexual function and impact of gynaecological cancer. Best Pract Res Clin Obstet Gynaecol. 2007;21(2):309–320. doi:10.1016/j.bpobgyn.2006.11.008.
   PubMed Web of Science ®Google Scholar
• Brotto LA, Heiman JR, Goff B, et al. A psychoeducational intervention for sexual dysfunction in women with gynecologic cancer. Arch Sex Behav. 2008;37(2):317–329. doi:10.1007/s10508-007-9196-x.
   PubMed Web of Science ®Google Scholar
• Bober SL, Recklitis CJ, Bakan J, et al. Addressing sexual dysfunction after risk‐reducing salpingo‐oophorectomy: effects of a brief, psychosexual intervention. J Sex Med. 2015;12(1):189–197. doi:10.1111/jsm.12713.
   PubMed Web of Science ®Google Scholar
• Ell K, Sanchez K, Vourlekis B, et al. Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. J Clin Oncol. 2005;23(13):3052–3060. doi:10.1200/JCO.2005.08.041.
   PubMed Web of Science ®Google Scholar
• Watts S, Prescott P, Mason J, et al. Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. 2015;5(11):e007618. doi:10.1136/bmjopen-2015-007618.
   PubMed Web of Science ®Google Scholar
• Brintzenhofe-Szoc KM, Levin TT, Li Y, et al. Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics. 2009;50(4):383–391. doi:10.1176/appi.psy.50.4.383.
   PubMed Web of Science ®Google Scholar
• Van Amstel FKP, Van Ham MAPC, Peters EJ, et al. Self-reported distress in patients with ovarian cancer: is it related to disease status? Int J Gynecological Cancer. 2015;25(2):229–235. doi:10.1097/IGC.0000000000000355.
   PubMed Web of Science ®Google Scholar
• Price MA, Butow PN, Costa DS, et al. Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their caregivers. Med J Aust. 2010;193(5):S52.
   PubMed Web of Science ®Google Scholar
• Brown AJ, Sun CC, Urbauer DL, et al. Feeling powerless: locus of control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients. Gynecol Oncol. 2015. doi:10.1016/j.ygyno.2015.05.005.
   Web of Science ®Google Scholar
• Bodurka-Bevers D, Basen-Engquist K, Carmack CL, et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol. 2000;78(3):302–308. doi:10.1006/gyno.2000.5908.
   PubMed Web of Science ®Google Scholar
• Rodin G, Lloyd N, Katz M, et al. The treatment of depression in cancer patients: a systematic review. Support Care Cancer. 2007;15(2):123–136. doi:10.1007/s00520-006-0145-3.
   PubMed Web of Science ®Google Scholar
• Lutgendorf SK, Anderson B, Ullrich P, et al. Quality of life and mood in women with gynecologic cancer: a one year prospective study. Cancer. 2002;94(1):131–140.
   PubMed Web of Science ®Google Scholar
• Hill EM. Quality of life and mental health among women with ovarian cancer: examining the role of emotional and instrumental social support seeking. Psychol Health Med. 2016 Jul;21(5):551–561.
   Web of Science ®Google Scholar
• Lebel S, Maheu C, Lefebvre M, et al. Addressing fear of cancer recurrence among women with cancer: a feasibility and preliminary outcome study. J Cancer Surviv. 2014;8(3):485–496. doi:10.1007/s11764-014-0357-3.
   PubMed Web of Science ®Google Scholar
• Smits A, Smits E, Lopes A, et al. Body mass index, physical activity and quality of life of ovarian cancer survivors: time to get moving? Gynecol Oncol. 2015;139(1):148–154. doi:10.1016/j.ygyno.2015.08.005.
   PubMed Web of Science ®Google Scholar
• Smits A, Lopes A, Das N, et al. Quality of life in ovarian cancer survivors: the influence of obesity. Int J Gynecological Cancer. 2015;25(4):616–621. doi:10.1097/IGC.0000000000000388.
   PubMed Web of Science ®Google Scholar
• Modesitt SC, Van Nagell JR Jr. The impact of obesity on the incidence and treatment of gynecologic cancers: a review. Obstet Gynecol Surv. 2005;60(10):683–692. doi:10.1097/01.ogx.0000180866.62409.01.
   PubMed Web of Science ®Google Scholar
• Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30(13):1553–1561. doi:10.1200/JCO.2011.39.9436.
   PubMed Web of Science ®Google Scholar
• Ben-Ami I, Vaknin Z, Schneider D, et al. Perioperative morbidity and mortality of gynecological oncologic surgery in elderly women. Int J Gynecological Cancer. 2006;16(1):452–457. doi:10.1111/j.1525-1438.2006.00478.x.
   PubMed Web of Science ®Google Scholar
• Duska L, Tew W, Moore K. Epithelial ovarian cancer in older women: defining the best management approach. American Society of Clinical Oncology educational book/ASCO. American Society of Clinical Oncology Meeting; Am Soc Clin Oncol Educ Book. 2015:e311–21.
   Google Scholar
• Teng F, Kalloger SE, Brotto L, et al. Determinants of quality of life in ovarian cancer survivors: a pilot study. JOGC. 2014;36(8):708–715.
   Google Scholar
• Matulonis U, Kornblith A, Lee H, et al. Long‐term adjustment of early-stage ovarian cancer survivors. Int J Gynecological Cancer. 2008;18(6):1183–1193. doi:10.1111/j.1525-1438.2007.01167.x.
   PubMed Web of Science ®Google Scholar
• Chase DM, Gibson SJ, Sumner DA, et al. Appropriate use of complementary and alternative medicine approaches in gynecologic cancers. Curr Treat Options Oncol. 2014;15(1):14–26. doi:10.1007/s11864-013-0269-x.
   PubMed Web of Science ®Google Scholar
• Von Gruenigen VE, Frasure HE, Jenison EL, et al. Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy. Gynecol Oncol. 2006;103(1):120–126. doi:10.1016/j.ygyno.2006.01.059.
   PubMed Web of Science ®Google Scholar
• Ferrell B, Smith S, Cullinane C, et al. Symptom concerns of women with ovarian cancer. J Pain Symptom Manag. 2003;25(6):528–538.
   PubMed Web of Science ®Google Scholar
• Swisher EM, Cohn DE, Goff BA, et al. Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol. 2002;84(3):363–367. doi:10.1006/gyno.2001.6515.
   PubMed Web of Science ®Google Scholar
• Gross AH, Cromwell J, Fonteyn M, et al. Hopelessness and complementary therapy use in patients with ovarian cancer. Cancer Nurs. 2013;36(4):256–264. doi:10.1097/NCC.0b013e31826f3bc4.
   PubMed Web of Science ®Google Scholar
• Miller B, Pittman B, Strong C. Gynecologic cancer patients’ psychosocial needs and their views on the physician’s role in meeting those needs. Int J Gynecological Cancer. 2003;13(2):111–119.
   PubMed Web of Science ®Google Scholar
• Beesley VL, Price MA, Webb PM, et al. Changes in supportive care needs after first-line treatment for ovarian cancer: identifying care priorities and risk factors for future unmet needs. Psychooncology. 2013;22(7):1565–1571. doi:10.1002/pon.3169.
   PubMed Web of Science ®Google Scholar
• Wenzel L, Huang HQ, Monk BJ, et al. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23(24):5605–5612. doi:10.1200/JCO.2005.08.147.
   PubMed Web of Science ®Google Scholar
• Wenzel LB, Huang HQ, Armstrong DK, et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(4):437–443. doi:10.1200/JCO.2006.07.3494.
   PubMed Web of Science ®Google Scholar
• Karvinen KH, Courneya KS, Campbell KL, et al. Exercise preferences of endometrial cancer survivors: a population-based study. Cancer Nurs. 2006;29(4):259–265.
   PubMed Web of Science ®Google Scholar